AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Learn more →

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

A Phase 1 Study To Estimate The Relative Bioavailability Of Fixed Combination Tablets Of Azithromycin And Chloroquine Compared To Co-Administered Individual Tablets Of Azithromycin And Chloroquine

Phase 1

Completed

Conditions: Malaria

Interventions: Drug: Fixed combination of Azithromycin and Chloroquine
Drug: Azithromycin and Chloroquine

First Posted Date: 2009-02-16

Last Posted Date: 2009-04-21

Lead Sponsor: Pfizer

Target Recruit Count: 40

Registration Number: NCT00844207

Locations: 🇺🇸
Pfizer Investigational Site, New Haven, Connecticut, United States

Observational Study Of Donepezil In Routine Clinical Practice

Terminated

Conditions: Alzheimer's Disease

Interventions: Other: donepezil

First Posted Date: 2009-02-13

Last Posted Date: 2014-03-13

Lead Sponsor: Pfizer

Target Recruit Count: 370

Registration Number: NCT00843115

Study Of Axitinib In Combination With Cisplatin And Capecitabine In Patients With Advanced Gastric Cancer

Phase 1

Completed

Conditions: Advanced Gastric Cancer
Stomach Neoplasms

Interventions: Drug: axitinib
Drug: capecitabine
Drug: cisplatin

First Posted Date: 2009-02-12

Last Posted Date: 2013-11-27

Lead Sponsor: Pfizer

Target Recruit Count: 22

Registration Number: NCT00842244

Locations: 🇰🇷
Pfizer Investigational Site, Seoul, Korea, Republic of

Immunogenicity, Safety and Interchangeability of Two Tbe Vaccines Administered According to a Conventional Schedule in Children

Phase 3

Completed

Conditions: Encephalitis, Tick-Borne

Interventions: Biological: Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)

First Posted Date: 2009-02-10

Last Posted Date: 2024-01-19

Lead Sponsor: Pfizer

Target Recruit Count: 302

Registration Number: NCT00840801

Locations: 🇦🇹
Unterer Graben 2, Eferding, Upper Austria, Austria
🇨🇿
Private surgery of General Practitioner for children and juveniles, Pardubice, Czechia
🇨🇿
University Hospital Hradec Kralove, Vaccinal center, Clinic of infectious diseases, Sokolská 581, Hradec Králové, Czechia

and more 2 locations

Confirming The Sitaxsentan Dose In Patients Undergoing Heart Surgery

Phase 2

Completed

Conditions: Cardiac Surgery Subjects
Subjects Undergoing CABG and/or Cardiac Valve Replacement

Interventions: Drug: Placebo
Drug: sitaxsentan (Thelin)

First Posted Date: 2009-02-06

Last Posted Date: 2022-09-08

Lead Sponsor: Pfizer

Target Recruit Count: 29

Registration Number: NCT00838383

Locations: 🇺🇸
University of Pennsylvania,, Philadelphia, Pennsylvania, United States
🇺🇸
The Chattanooga Heart Institute, Chattanooga, Tennessee, United States
🇺🇸
Medical University of South Carolina, Charleston, South Carolina, United States

A Study in Normal Healthy People, Testing Different Versions of a Pill That Will be Used to Treat Rheumatoid Arthritis.

Phase 1

Completed

Conditions: Rheumatoid Arthritis
Healthy Volunteers

Interventions: Drug: CE-224,535
Drug: CE 224,535

First Posted Date: 2009-02-06

Last Posted Date: 2009-10-14

Lead Sponsor: Pfizer

Target Recruit Count: 11

Registration Number: NCT00838058

Locations: 🇺🇸
Pfizer Investigational Site, New Haven, Connecticut, United States

A Phase 3 Study To Evaluate The Safety And Tolerability Of Dimebon Patients With Mild To Moderate Alzheimer's Disease

Phase 3

Completed

Conditions: Alzheimer's Disease

Interventions: Drug: Placebo
Drug: Dimebon

First Posted Date: 2009-02-06

Last Posted Date: 2018-12-06

Lead Sponsor: Pfizer

Target Recruit Count: 742

Registration Number: NCT00838110

Locations: 🇵🇷
Pfizer Investigational Site, San Juan, Puerto Rico

Phase I Study Of The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple Intravenously Administered Doses Of PF-04236921 In Patients With Rheumatoid Arthritis

Phase 1

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Placebo
Drug: dose level 1
Drug: dose level 2
Drug: dose level 3
Drug: dose level 4

First Posted Date: 2009-02-06

Last Posted Date: 2018-11-02

Lead Sponsor: Pfizer

Target Recruit Count: 41

Registration Number: NCT00838565

Locations: 🇺🇸
Altoona Center for Clinical Research, Duncansville, Pennsylvania, United States
🇺🇸
Millennium Research, Ormond Beach, Florida, United States
🇰🇷
Inha University Hospital, Medicine/Rheumatology, Incheon, Korea, Republic of

and more 5 locations

Axitinib (AG-013736) With Or Without Dose Titration (Increase) In Patients With Kidney Cancer

Phase 2

Completed

Conditions: Carcinoma, Renal Cell

Interventions: Drug: axitinib

First Posted Date: 2009-02-04

Last Posted Date: 2017-05-30

Lead Sponsor: Pfizer

Target Recruit Count: 213

Registration Number: NCT00835978

Locations: 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States

and more 60 locations

A Multiple Dose Trial Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-04457845 in Healthy Volunteers

Phase 1

Completed

Conditions: Acute Pain
Chronic Pain

Interventions: Drug: PF-04457845, FAAH inhibitor

First Posted Date: 2009-02-04

Last Posted Date: 2009-08-06

Lead Sponsor: Pfizer

Target Recruit Count: 41

Registration Number: NCT00836082

Locations: 🇸🇬
Pfizer Investigational Site, Singapore, Singapore

Home Terms & Conditions Privacy Policy